Amid apprehension in some international markets over the recent export restrictions imposed by India on a basket of active pharmaceutical ingredients (APIs) and formulations, there appears to be ongoing dialog between industry and the government to strike a balance to safeguard both domestic medicines security and commercial opportunities.
India Export Restrictions: Balancing Tweaks In Store?
Some transitional arrangements may help Indian drug firms process export obligations already underway prior to recent government restrictions designed to safeguard domestic supplies against the backdrop of supply chain stress due to the coronavirus outbreak. But will the Indian government tweak the restrictions to balance home demands and exports?
More from India
More from Asia
• By
A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.
• By
Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.
• By
While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.